Eisai Inc - Strategic SWOT Analysis Review

  • ID: 1495870
  • SWOT Analysis
  • 35 pages
  • GlobalData
  • Eisai Co
1 of 5

FEATURED COMPANIES

  • Abraxis BioScience Inc
  • Adlyfe Inc
  • AstraZeneca Plc
  • Ceregene Inc
  • Koronis Pharma Inc
  • Salix Pharmaceuticals Ltd
  • MORE
Eisai Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - The author’s summarization of the company’s business strategy.
- SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.
- Key manufacturing facilities - A list of key manufacturing facilities of the company.

Highlights

Eisai Inc (Eisai) is a healthcare company, which focuses on the discovery, development and marketing of pharmaceutical products. The company's major products include Aricept for Alzheimer’s treatment, Aciphex for acid reflux, Akynzeo for nausea and vomiting dring the course of cancer chemotherapy, Aloxi anti-nausea medication injection, Banzel for adjunctive treatment and Panretin for the treatment of skin lesions in AIDS-related Kaposi's sarcoma.

The company’s research and development activities focus on therapeutic areas such as neuroscience; cancer, antibody-based programs; vascular, inflammatory and immunological reaction. Eisai established partnerships and collaborations with global companies such as Pfizer Inc., Janssen Pharmaceutica Inc., and Elan Pharma International Limited and Elan Pharmaceutical Inc for the development and distribution of drugs. The company is a subsidiary of Eisai Co., Ltd. and is headquartered in New Jersey, the US.

Eisai Inc Key Recent Developments

Dec 01, 2016: Rebecca Jolley appointed Senior Vice President Americas Commercial, Oncology Business Group at Eisai
Sep 15, 2016: Eisai Establishes AiM Institute to Discover Human Biology Driven Precision Medicines
Jun 29, 2016: Eisai Highlights its Strong Pipeline and Innovative Approach to R&D at Company's U.S. Scientific Day
May 24, 2016: Maria Garrigan appointed Vice President, Global Regulatory Strategy, Oncology Business Group at Eisai
Apr 20, 2016: Dr. Avinash Desai appointed Vice President, Americas Oncology Medical Affairs, Oncology Business Group at Eisai

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with this detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abraxis BioScience Inc
  • Adlyfe Inc
  • AstraZeneca Plc
  • Ceregene Inc
  • Koronis Pharma Inc
  • Salix Pharmaceuticals Ltd
  • MORE
List of Tables

List of Figures

Section 1 - About the Company

Eisai Inc - Key Facts

Eisai Inc - Key Employees

Eisai Inc - Key Employee Biographies

Eisai Inc - Major Products and Services

Eisai Inc - History

Eisai Inc - Company Statement

Eisai Inc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 - Company Analysis

Eisai Inc - Business Description

Eisai Inc - Corporate Strategy

Eisai Inc - SWOT Analysis

SWOT Analysis - Overview

Eisai Inc - Strengths

Eisai Inc - Weaknesses

Eisai Inc - Opportunities

Eisai Inc - Threats

Eisai Inc - Key Competitors

Section 3 - Company’s Lifesciences Financial Deals and Alliances

Eisai Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017

Eisai Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017

Eisai Inc, Recent Deals Summary

Section 4 - Company’s Recent Developments

Dec 01, 2016: Rebecca Jolley appointed Senior Vice President Americas Commercial, Oncology Business Group at Eisai

Sep 15, 2016: Eisai Establishes AiM Institute to Discover Human Biology Driven Precision Medicines

Jun 29, 2016: Eisai Highlights its Strong Pipeline and Innovative Approach to R&D at Company's U.S. Scientific Day

May 24, 2016: Maria Garrigan appointed Vice President, Global Regulatory Strategy, Oncology Business Group at Eisai

Apr 20, 2016: Dr. Avinash Desai appointed Vice President, Americas Oncology Medical Affairs, Oncology Business Group at Eisai

Apr 11, 2016: Beyhan Zaim appointed Vice President Commercial Development & Alzheimer's Disease Global Lead, Neurology Business Group at Eisai

Apr 06, 2016: Paul Hawthorne appointed Senior Vice President, U.S. Commercial, Neurology Business Group at Eisai

Mar 30, 2016: Global Drug Maker Eisai Signs Three-Year Contract Extension For CSC’s Total Regulatory Solution as-a-Service

Feb 16, 2016: Dementia Consortium signs new pharmaceutical partner AbbVie

Section 5 - Appendix

Methodology

About

Disclaimer

List of Tables

Eisai Inc, Key Facts

Eisai Inc, Key Employees

Eisai Inc, Key Employee Biographies

Eisai Inc, Major Products and Services

Eisai Inc, History

Eisai Inc, Other Locations

Eisai Inc, Subsidiaries

Eisai Inc, Key Competitors

Eisai Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017

Eisai Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017

Eisai Inc, Recent Deals Summary

List of Figures

Eisai Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017

Eisai Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • White River Health System
  • Wellstat Therapeutics Corp
  • Salix Pharmaceuticals Ltd
  • Research Foundation for Mental Hygiene Inc
  • Predictive Biosciences Inc
  • Koronis Pharma Inc
  • Ceregene Inc
  • AstraZeneca Plc
  • Adlyfe Inc
  • Abraxis BioScience Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll